Latest Healthcare News

Clever Culture Systems has expanded its APAS Independence installed base to 27 instruments globally and surpassed $1 million in annual recurring revenue, underpinned by strong sales momentum and customer validation.

Firebrick Pharma has commenced commercial manufacturing and export of its new Nasodine Throat Spray, marking a significant step in its international expansion. The company also reported a 15% increase in cash sales and reduced operating costs, signalling improving financial health.

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.

HeraMED Limited has completed a $3.2 million placement to fund its global rollout of digital maternity care solutions, backed by new and existing institutional investors.

Adheris Health has received the final $6.1 million holdback payment from its Australian and New Zealand business sale, bringing total proceeds to $33.1 million and setting the stage for future earn-out payments.

EMVision Medical Devices reports strong progress in its emu™ Brain Scanner clinical trials, expanding recruitment across seven leading stroke hospitals and introducing new software features to enhance scan quality.

Nexsen Limited has won a $500,000 non-dilutive grant to extend its rapid Group B Streptococcus diagnostic technology into neonatal care, opening a significant new market opportunity.

Singular Health Group has advanced its U.S. commercial footprint with the deployment of 500 new licences under its PNS contract and secured FDA clearance for its cloud-based 3DICOM MD® platform, positioning the company for significant growth.

Cyclopharm’s Technegas has been recognised as the preferred ventilation agent in a pivotal draft US lung imaging guideline, signalling a major boost for its adoption in American clinical practice.

Biome Australia Limited has delivered its strongest quarterly financial performance to date, with sales revenue surging 41% year-on-year to $6.5 million and maintaining eight consecutive quarters of positive EBITDA.

Island Pharmaceuticals has secured key regulatory milestones for its antiviral Galidesivir, including FDA confirmation of the Animal Rule pathway and Priority Review Voucher eligibility, while strengthening US biodefense ties and expanding patent protection.

Cyclopharm Limited confirms its insurer has assumed responsibility for defending the company in ongoing legal proceedings initiated by 4DMedical Limited. This development marks a significant step in managing the dispute’s financial and operational risks.